CapEx at other companies
Other financials
Where this comes from
Reported directly by BioMarin Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment.
The official record: BioMarin Pharmaceuticals’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about BioMarin Pharmaceuticals's capex.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is BioMarin Pharmaceuticals's capex?
- BioMarin Pharmaceuticals (BMRN) reported capex of $20.92M in Q1 2026.
- How has BioMarin Pharmaceuticals's capex changed year-over-year?
- BioMarin Pharmaceuticals's capex increased by 24.8% year-over-year, from $16.77M to $20.92M.
- What is the long-term trend for BioMarin Pharmaceuticals's capex?
- Over 4 years (2021 to 2025), BioMarin Pharmaceuticals's capex has grown at a 1.9% compound annual growth rate (CAGR), from $95.58M to $103.04M.
- What does capex mean?
- Cash spent on physical assets like buildings and equipment.
- How do you interpret capex?
- High spending indicates growth and infrastructure investment; low spending may suggest a focus on asset-light operations or capital preservation.
- How does capex compare across companies?
- Standard metric; peers in the same industry should have similar capital intensity ratios.